Insmed's lung infection drug succeeds in late-stage trial

July 1 Mon Jul 1, 2013 7:25am EDT

July 1 (Reuters) - Insmed Inc said a late-stage trial of its experimental lung infection drug showed the therapy was as effective as another approved treatment.

The drug, Arikace, was being tested as a treatment for a bacterial infection in cystic fibrosis patients. The trial met its main goal of showing Arikace was not inferior to Tovi, Novartis's drug for the same infection.